We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sensitive Test Developed for Sleeping Sickness

By LabMedica International staff writers
Posted on 05 Jun 2012
Proteins imitating typical parts of the sleeping sickness parasite can be used in more efficient diagnostic tests, without the need for culturing dangerous parasites. More...


In the regions where Trypanosoma brucei gambiense, the causative agent of sleeping sickness is found, medical workers for decades already use a rapid diagnostic test, to screen millions of people each year on the presence of antibodies in their blood.

A scientist at the Antwerp Institute of Tropical Medicine (Belgium) has developed a new and better test by trying to synthesize artificial targets. These 'mimotopes' mimic only a part of the original target protein, but still are sufficient to react with the patient's antibodies. The investigator produced mimotopes that are reliable and react with infected patients' serum. These mimotopes now can be the base for a new generation of rapid diagnostic tests for sleeping sickness.

In the original tests the antibodies are demonstrated by presenting them targets they will also recognize and attack on real trypanosomes such as the variable surface glycoprotein that cover the parasite as a mantle. When antibody and target react, the test is positive and is made visible by for instance a color change or a clotting. Today those targets are obtained from living parasites that are raised in laboratory animals, and are a constant danger for the laboratory technicians.

In an early stage, the disease is easy to treat, but once the brain is invaded, the treatment becomes more complex and physicians must use medicines with dangerous, even deadly, side effects. Therefore, it is important to detect the infection early. Patients become disoriented, their sleeping pattern disintegrates, and they get motor and mental problems. This inevitably leads to coma and death. According to the World Health Organization (WHO; Geneva, Switzerland) estimates, sleeping sickness claims 10,000 to 20,000 lives each year. In recent years, the number of cases has come down substantially, thanks to campaigns against the disease, so error margins that were acceptable in the old days, because the tests still saved so many lives, now become inadmissible.

Related Links:

Antwerp Institute of Tropical Medicine
World Health Organization



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.